Sartorius adds biologics testing through acquisition of CRO BioOutsource

By Dan Stanton contact

- Last updated on GMT

BioOutsource HQ in Glasgow, Scotland
BioOutsource HQ in Glasgow, Scotland

Related tags: Clinical trial, Pharmaceutical industry

Sartorius has expanded its biopharma services to include contract testing by buying CRO BioOutsource.

Vendor of bioprocessing equipment Sartorius Stedim Biotech (SSB) has today announced it is moving into the drug development services industry through the acquisition of Glasgow, UK-based contract research organisation (CRO) BioOutsource.

The deal – of which financials have not been divulged – will see Sartorius add biopharma testing services including safety monitoring, drug characterisation and comparability testing of biologics and vaccines.

“By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing,”​ SSB Board member Reinhard Vogt said.

Gerry MacKay, CEO of BioOutsource, added the deal would allow the CRO to “scale our business to the next level and invest in new adjacent services,”​ as well as increase its global standing.

“As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing.”

BioOutsource employs approximately 85 staff and reported revenues last year of around €9m ($10m).

Sartorius investor relations director Andreas Theisen told us the deal was less about acquiring a CRO per se, and was instead focused on expanding Sartorius’ service portfolio.

We looked at the services we offer and decided that BioOutsource’s analytical capabilities would be a useful addition to our portfolio​.”

He declined to comment about integration plans.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more